Central hypersomnias are diseases manifested in excessive daytime sleepiness (EDS) not caused by disturbed nocturnal sleep or misaligned circadian rhythms. Central hypersomnias includes narcolepsy with and without cataplexy, recurrent hypersomnia, idiopathic hypersomnia, with and without long sleep time, behaviorally induced insufficient sleep syndrome, hypersomnia and narcolepsy due to medical conditions, and finally hypersomnia induced by substance intake. The Epworth Sleepiness Scale is a subjective tool mostly used for EDS assessment, while the Multiple Sleep Latency Test serves as an objective diagnostic method for narcolepsy and idiopathic hypersomnias. As for symptomatic therapy of EDS, the central nervous system stimulants modafinil and methylphenidate seem to work well in most cases and in narcolepsy and Parkinson's disease; sodium oxybate also has notable therapeutic value.

Department of Neurology and Center of Clinical Neuroscience 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Katerinska 30 Prague Czech Republic

Zobrazit více v PubMed

Ali M., Auger R., Slocumb N., Morgenthaler T. (2009) Idiopathic hypersomnia: clinical features and response to treatment. J Clin Sleep Med 5: 562–568 PubMed PMC

American Academy of Sleep Medicine (2005a) The International Classification of Sleep Disorders: Diagnostic and Coding Manual, 2nd edn Westchester, Ill.: American Academy of Sleep Medicine

American Academy of Sleep Medicine (2005b) Practice parameters for clinical use of the Multiple Sleep Latency Test and the Maintenance of Wakefulness Test. Sleep 28: 113–121 PubMed

Arnulf I., Zeitzer J., File J., Farber N., Mignot E. (2005) Kleine–Levin syndrome: a systematic review of 186 cases in the literature. Brain 128: 2763–2776 PubMed

Baier P., Hallschmid M., Seeck-Hirschner M., Weinhold S., Burkert S., Diessner N., et al. (2011) Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy. Sleep Med 12: 941–946 PubMed

Bassetti C. (2011) Sleep and stroke. In: Kryger M., Roth T., Dement W. (eds), Principles and Practice of Sleep Medicine, 5th edn St.Louis: Elsevier Saunders, pp. 830–993

Baumann C., Werth E., Stocker R., Ludwig S., Bassetti C. (2007) Sleep–wake disturbances 6 months after traumatic brain injury: a prospective study. Brain 130: 1873–1883 PubMed

Billiard M., Bassetti C., Dauvilliers Y., Dolenc-Groselj L., Lammers G., Mayer G., et al. (2006) EFNS guidelines on management of narcolepsy. Eur J Neurol 13: 1035–1048 PubMed

Billiard M., Besset A., Montplaisir J., Laffont F., Goldenberg F., Weill J., et al. (1994) Modafinil: a double-blind multicentric study. Sleep 17(8 Suppl.): S107–S112 PubMed

Billiard M., Jaussent I., Dauvilliers Y., Besset A. (2011) Recurrent hypersomnia: a review of 339 cases. Sleep Med Rev 15: 247–257 PubMed

Black J., Houghton W. (2006) Sodium oxybate improves excessive daytime sleepiness in narcolepsy. Sleep 29: 939–946 PubMed

Black J., Pardi D., Hornfeldt C., Inhaber N. (2010) The nightly use of sodium oxybate is associated with a reduction in nocturnal sleep disruption: a double-blind, placebo-controlled study in patients with narcolepsy. J Clin Sleep Med 6: 596–602 PubMed PMC

Boscolo-Berto R., Viel G., Montagnese S., Raduazzo D., Ferrara S., Dauvilliers Y. (2011) Narcolepsy and effectiveness of gamma-hydroxybutyrate (GHB): A systematic review and meta-analysis of randomized controlled trials. Sleep Med Rev, in press PubMed

Broughton R., Fleming J., George C., Hill J., Kryger M., Moldofsky H., et al. (1997) Randomized, double-blind, placebo-controlled crossover trial of modafinil in the treatment of excessive daytime sleepiness in narcolepsy. Neurology 49: 444–451 PubMed

Carskadon M., Dement W., Mitler M., Roth T., Westbrook P., Keenan S. (1986) Guidelines for the Multiple Sleep Latency Test (MSLT): a standard measure of sleepiness. Sleep 9: 519–524 PubMed

Coelho F., Georgsson H., Murray B. (2011) Benefit of repeat Multiple Sleep Latency Testing in confirming a possible narcolepsy diagnosis. J Clin Neurophysiol 28: 412–414 PubMed

Compta Y., Iranzo A., Santamaria J., Casamitjana R., Graus F. (2007) REM sleep behavior disorder and narcoleptic features in anti-Ma2-associated encephalitis. Sleep 30: 767–769 PubMed PMC

Culebras A. (2011) Other neurologic disorders. In: Kryger M., Roth T., Dement W. (eds), Principles and Practice of Sleep Medicine. St.Louis: Elsevier Saunders, pp. 1064–1074

Dauvilliers Y., Abril B., Mas E., Michel F., Tafti M. (2009) Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 73: 1333–1334 PubMed

Dauvilliers Y., Arnulf I., Mignot E. (2007) Narcolepsy with cataplexy. Lancet 369: 499–511 PubMed

European Medicines Agency (2005) Sodium Oxybate. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000593/human_med_001163.jsp&mid=WC0b01ac058001d124

Food and Drug Administration (2012) Drug Information: Modafinil. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2007/020717s020s013s018lbl.pdf?utm_campaign%20/

Frucht S., Rogers J., Greene P., Gordon M., Fahn S. (1999) Falling asleep at the wheel: motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 52: 1908–1910 PubMed

Harsh J., Hayduk R., Rosenberg R., Wesnes K., Walsh J., Arora S., et al. (2006) The efficacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy. Curr Med Res Opin 22: 761–774 PubMed

Hogl B., Saletu M., Brandauer E., Glatzl S., Frauscher B., Seppi K., et al. (2002) Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep 25: 905–909 PubMed

Ivanenko A. (2008) Sleep and Psychiatric Disorders in Children and Adolescents. London: Informa Healthcare; http://www.loc.gov/catdir/enhancements/fy0806/2007049955-d.html

Jha A., Weintraub A., Allshouse A., Morey C., Cusick C., Kittelson J., et al. (2008) A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury. J Head Trauma Rehabil 23: 52–63 PubMed

Johns M. (1991) A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 14: 540–545 PubMed

Kaiser P., Valko P., Werth E., Thomann J., Meier J., Stocker R., et al. (2010) Modafinil ameliorates excessive daytime sleepiness after traumatic brain injury. Neurology 75: 1780–1785 PubMed

Kanbayashi T., Shimohata T., Nakashima I., Yaguchi H., Yabe I., Nishizawa M., et al. (2009) Symptomatic narcolepsy in patients with neuromyelitis optica and multiple sclerosis: new neurochemical and immunological implications. Arch Neurol 66: 1563–1566 PubMed

Knudsen S., Jennum P., Korsholm K., Sheikh S., Gammeltoft S., Frederiksen J. (2008) Normal levels of cerebrospinal fluid hypocretin-1 and daytime sleepiness during attacks of relapsing–remitting multiple sclerosis and monosymptomatic optic neuritis. Mult Scler 14: 734–738 PubMed

Kornum B., Faraco J., Mignot E. (2011) Narcolepsy with hypocretin/orexin deficiency, infections and autoimmunity of the brain. Curr Opin Neurobiol 21: 897–903 PubMed

Lankford D. (2008) Armodafinil: a new treatment for excessive sleepiness. Expert Opin Investig Drugs 17: 565–573 PubMed

Lavault S., Dauvilliers Y., Drouot X., Leu-Semenescu S., Golmard J., Lecendreux M., et al. (2011) Benefit and risk of modafinil in idiopathic hypersomnia vs. narcolepsy with cataplexy. Sleep Med 12: 550–556 PubMed

Lecendreux M., Bruni O., Franco P., Gringras P., Konofal E., Nevsimalova S., et al. (2012) Clinical experience suggests that modafinil is an effective and safe treatment for paediatric narcolepsy. J Sleep Res, in press PubMed

Littner M., Johnson S., McCall W., Anderson W., Davila D., Hartse S., et al. (2001) Practice parameters for the treatment of narcolepsy: an update for 2000. Sleep 24: 451–466 PubMed

Mignot E., Hayduk R., Black J., Grumet F., Guilleminault C. (1997) HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 20: 1012–1020 PubMed

Mignot E., Lammers G., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. (2002) The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 59: 1553–1562 PubMed

Morgenthaler T., Kapur V., Brown T., Swick T., Alessi C., Aurora R., et al. (2007) Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin. Sleep 30: 1705–1711 PubMed PMC

Ondo W., Fayle R., Atassi F., Jankovic J. (2005) Modafinil for daytime somnolence in Parkinson’s disease: double blind, placebo controlled parallel trial. J Neurol Neurosurg Psychiatry 76: 1636–1639 PubMed PMC

Ondo W., Perkins T., Swick T., Hull K., Jr, Jimenez J., Garris T., et al. (2008) Sodium oxybate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study. Arch Neurol 65: 1337–1340 PubMed

Ozaki A., Inoue Y., Hayashida K., Nakajima T., Honda M., Usui A., et al. (2012) Quality of life in patients with narcolepsy with cataplexy, narcolepsy without cataplexy, and idiopathic hypersomnia without long sleep time: Comparison between patients on psychostimulants, drug-naive patients and the general Japanese population. Sleep Med 13: 200–206 PubMed

Poppe M., Friebel D., Reuner U., Todt H., Koch R., Heubner G. (2003) The Kleine–Levin syndrome - effects of treatment with lithium. Neuropediatrics 34: 113–119 PubMed

Roth T., Schwartz J., Hirshkowitz M., Erman M., Dayno J., Arora S. (2007) Evaluation of the safety of modafinil for treatment of excessive sleepiness. J Clin Sleep Med 3: 595–602 PubMed PMC

Schwartz J. (2011) The histamine H3 receptor: from discovery to clinical trials with pitolisant. Br J Pharmacol 163: 713–721 PubMed PMC

Shoham S., Davenne D., Cady A., Dinarello C., Krueger J. (1987) Recombinant tumor necrosis factor and interleukin 1 enhance slow-wave sleep. Am J Physiol 253: R142–R149 PubMed

Sonka K., Kemlink D., Buskova J., Pretl M., Srutkova Z., Maurovich Horvat E., et al. (2010) Obesity accompanies narcolepsy with cataplexy but not narcolepsy without cataplexy. Neuro Endocrinol Lett 31: 631–634 PubMed

US Modafinil in Narcolepsy Multicenter Study Group (1998) Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. Ann Neurol 43: 88–97 PubMed

US Modafinil in Narcolepsy Multicenter Study Group (2000) Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy. Neurology 54: 1166–1175 PubMed

Vavrova J., Kemlink D., Sonka K., Havrdova E., Horakova D., Pardini B., et al. (2012) Restless legs syndrome in Czech patients with multiple sclerosis: an epidemiological and genetic study. Sleep Med, in press PubMed

Vernet C., Leu-Semenescu S., Buzare M., Arnulf I. (2010) Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness. J Sleep Res 19: 525–534 PubMed

von Economo C. (1930) Sleep as a problem of localisation. J Nerv Ment Dis 71: 249–259

Winkelman J., Plante D. (2010) Foundations of Psychiatric Sleep Medicine. Cambridge: Cambridge University Press

Wise M., Arand D., Auger R., Brooks S., Watson N. (2007) Treatment of narcolepsy and other hypersomnias of central origin. Sleep 30: 1712–1727 PubMed PMC

Xyrem International Study Group (2005) Further evidence supporting the use of sodium oxybate for the treatment of cataplexy: a double-blind, placebo-controlled study in 228 patients. Sleep Med 6: 415–421 PubMed

Xyrem Multicenter Study Group (2002) A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered sodium oxybate with placebo for the treatment of narcolepsy. Sleep 25: 42–49 PubMed

Xyrem Multicenter Study Group (2003) A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy. Sleep 26: 31–35 PubMed

Xyrem Multicenter Study Group (2004) Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy. Sleep Med 5: 119–123 PubMed

Zifko U., Rupp M., Schwarz S., Zipko H., Maida E. (2002) Modafinil in treatment of fatigue in multiple sclerosis. Results of an open-label study. J Neurol 249: 983–987 PubMed

Idiopathic Hypersomnia-A Dynamic Simulation Model